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A growing emphasis on using cell-based assays for com-
pound screening and enzyme activity is fueled by the need
to decrease costs, increase success rates, and identify fail-
ures during discovery and preclinical development. More-
over, the growth in cell-based screening has led to the
development of novel cell lines and technologies to
increase the throughput and data output of cell-based
assays. Therefore, we have also developed a new reporter
system that allows monitoring of HIV-1 protease activity
and susceptibility to protease inhibitors in living cells.
Our aim was to construct a cell-based assay for assessing
the activity of intracellular HIV protease, use it to screen
protease inhibitors and test HIV susceptibility to these
drugs. Functional bioassay for resistance was constructed
without the need to culture infectious HIV. These assays
are based on processing of recombinant reporter proteins
in mammalian cells using wild-type PR or a pool of
patient-derived PR sequences. Assays not involving infec-
tious HIV should be simpler, faster, safer, and more eco-
nomic and allow implementation in clinical routine labs,
which are generally not equipped for virus culture. More-
over, its application for searching inhibitors of this impor-
tant enzyme will provide faster, high-throughput and
reliable results.
The working hypothesis was to test if a transactivator pro-
tein conjugated to the cytoplasmic portion of a cellular
receptor, via the respective cleavage peptide, could be
used as an indicator of HIV protease susceptibility. This
assay was constructed in a cell line that expresses an indi-
cator protein under the inducible action of the transacti-
vator. The cleavage of the transactivator protein by the
action of the protease resulted in the expression of luci-
ferase or β-galactosidase. In preliminary experiments, the
signal obtained correlates with the intracellular activity of
the protease. The optimized cleavage assay is currently
being used for testing current protease inhibitors to com-
pare the IC50 values to reference virologic assays.
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